ReviewThe Journal of allergy and clinical immunology2017
Half-life of IgE in serum and skin: Consequences for anti-IgE therapy in patients with allergic disease.
Review in The Journal of allergy and clinical immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed.
- The effect of 12-week high-doseFrontiers in immunology · 2024Trial
- Trial
- Dialyzer Reactions Revisited: A Fresh Perspective.Kidney medicine · 2026Review
- A Case for Anti-IgE Vaccination.Allergy · 2026Review
- Seasonality of Serum Allergen-Specific IgE Levels in Scandinavian Dogs Suspected of Allergy.Veterinary sciences · 2026Article
- AllergoOncology in Review: Harnessing Allergy in the Field of Oncology to Improve Patient Outcomes.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026Review
- Oral Immunotherapy-Induced Changes in IgE, IgG, and IgA: A Review of Antibody Isotype Shifts and Their Clinical Relevance in Food Allergy.Antibodies (Basel, Switzerland) · 2026Review
- Article
- Hybrid IgE-IgG1 antibodies (IgEG): a new antibody class that combines IgE and IgG functionality.mAbs · 2025Article
- IgE based therapeutics are an emerging modality in cancer treatment.Discover oncology · 2025Review
- Progress and Prospects of Transdermal Treatment of Allergic Skin Diseases with Natural Drugs based on Nanotechnology.AAPS PharmSciTech · 2025Review
- Article
- Advances in Food Allergy Immunotherapy: Current Strategies and Role of Antibodies Isotypes.Cells · 2025Review
- Maternal IgE Influence on Fetal and Infant Health.Immunological reviews · 2025Review
- Structural and Functional Insights Into IgE Receptor Interactions and Disruptive Inhibition.Immunological reviews · 2025Review
- Hyperinflammatory repolarisation of ovarian cancer patient macrophages by anti-tumour IgE antibody, MOv18, restricts an immunosuppressive macrophage:Treg cell interaction.Nature communications · 2025Article
- Allergen Immunotherapy: Pitfalls, Perks and Unexpected Allies.International journal of molecular sciences · 2025Review
- Review
- The role of immunoglobulin E in non-atopic disorders.Frontiers in immunology · 2025Review
- Therapeutic monoclonal antibodies in allergy: Targeting IgE, cytokine, and alarmin pathways.Immunological reviews · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
We present results from clinical studies on plasma infusion done in the late 1970s in patients with hypogammaglobulinemia in which we documented the short half-life of both total and allergen-specific IgE in serum. The development of specific allergic sensitization in the skin of those patients followed by the gradual decrease in sensitization over 50 days was also documented. The data are included here along with a discussion of the existing literature about the half-life of IgE in both the circulation and skin. This rostrum reinterprets the earlier clinical studies in light of new insights and mechanisms that could explain the rapid removal of IgE from the circulation. These mechanisms have clinical implications that relate to the increasing use of anti-IgE mAbs for the treatment of allergic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.